BloombergLean L·
Cancer Drugmaker Parabilis Seeks $475 Million in US IPO
Parabilis Medicines, a clinical-stage cancer drug developer, is seeking to raise $475 million in an initial public offering.
Read at Bloomberg →
Markets · 1 sources covering this
Cancer Drugmaker Parabilis Seeks $475 Million in US IPO
Parabilis Medicines, a clinical-stage cancer drug developer, is seeking to raise $475 million in an initial public offering.
Coverage spectrum
1 L · 0 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/039ce0424a5bb994510fd8d327744150aacc96a8" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Cancer Drugmaker Parabilis Seeks $475 Million in US IPO"></iframe>
